ArticleBiogerontology2026
Consumption of Terminalia catappa powder: modulation of lipid metabolism, reduction of cardiovascular risk, and hepatic protection in aged Wistar rats.
Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to evaluate the impact of Terminalia catappa powder consumption on biochemical, morphometric, cardiovascular risk, and hepatic markers in aged Wistar rats. Three groups were formed (n = 10): the control group (CG) was treated with distilled water, and the P500 and P1000 groups were treated with 500 and 1000 mg/kg of Terminalia catappa powder, respectively. Animal body weight and food intake were monitored weekly. At the end of the study, fecal samples were collected for cholesterol, triglycerides (TG), and fatty acid analysis. Additionally, murinometric and biochemical parameters were assessed. Hepatic tissue was harvested to evaluate cholesterol, TG, and malondialdehyde (MDA) levels. Food consumption and body weight showed no significant differences. In the P500 and P1000 groups, retroperitoneal fat weight was reduced, with P1000 also decreasing triglycerides (TG) and HDL levels. Both experimental groups registered lowered total cholesterol (TC), TG, and hepatic malondialdehyde (MDA) levels, with more pronounced effects in P1000, which also exhibited a higher proportion of unsaturated fatty acids. Fecal cholesterol increased in P1000, while fecal TG levels decreased in both treated groups. P1000 registered reduced cardiovascular and coronary risk indices and achieved the greatest reduction in MDA levels in coronary tissue. These results suggest that Terminalia catappa improves plasma and hepatic lipid metabolism, reduces body fat, and attenuates lipid peroxidation. Given its effects on cardiovascular risk factors, consumption of this fruit may contribute to reduced cardiovascular and coronary risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.